SG10201401879TA - Human cgrp receptor binding proteins - Google Patents

Human cgrp receptor binding proteins

Info

Publication number
SG10201401879TA
SG10201401879TA SG10201401879TA SG10201401879TA SG10201401879TA SG 10201401879T A SG10201401879T A SG 10201401879TA SG 10201401879T A SG10201401879T A SG 10201401879TA SG 10201401879T A SG10201401879T A SG 10201401879TA SG 10201401879T A SG10201401879T A SG 10201401879TA
Authority
SG
Singapore
Prior art keywords
binding proteins
receptor binding
cgrp receptor
human cgrp
human
Prior art date
Application number
SG10201401879TA
Inventor
Thomas C Boone
David W Brankow
Jr Colin V Gegg
Shaw-Fen Sylvia Hu
Chadwick T King
Hsieng Sen Lu
Licheng Shi
Cen Xu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US20356908P priority Critical
Priority to US26462209P priority
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of SG10201401879TA publication Critical patent/SG10201401879TA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
SG10201401879TA 2008-12-23 2009-12-18 Human cgrp receptor binding proteins SG10201401879TA (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US20356908P true 2008-12-23 2008-12-23
US26462209P true 2009-11-25 2009-11-25

Publications (1)

Publication Number Publication Date
SG10201401879TA true SG10201401879TA (en) 2014-06-27

Family

ID=41718325

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201401879TA SG10201401879TA (en) 2008-12-23 2009-12-18 Human cgrp receptor binding proteins
SG2011045556A SG172307A1 (en) 2008-12-23 2009-12-18 Human cgrp receptor binding proteins

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2011045556A SG172307A1 (en) 2008-12-23 2009-12-18 Human cgrp receptor binding proteins

Country Status (33)

Country Link
US (4) US9102731B2 (en)
EP (2) EP2379594B1 (en)
JP (3) JP5761805B2 (en)
KR (3) KR20180043850A (en)
CN (1) CN102348722B (en)
AR (1) AR074857A1 (en)
AU (1) AU2009330175C1 (en)
BR (1) BRPI0922505A2 (en)
CA (1) CA2746858C (en)
CO (1) CO6400232A2 (en)
CR (1) CR20110400A (en)
CY (1) CY1119465T1 (en)
DK (1) DK2379594T3 (en)
EA (2) EA031320B1 (en)
ES (1) ES2643835T3 (en)
HR (1) HRP20171690T1 (en)
HU (2) HUE034506T2 (en)
IL (2) IL213429A (en)
LT (2) LT2379594T (en)
MA (1) MA32982B1 (en)
MX (1) MX2011006804A (en)
NL (1) NL300961I2 (en)
NO (1) NO2018042I1 (en)
NZ (1) NZ623541A (en)
PE (1) PE04272012A1 (en)
PT (1) PT2379594T (en)
RS (1) RS56567B1 (en)
SG (2) SG10201401879TA (en)
SI (1) SI2379594T1 (en)
TN (1) TN2011000283A1 (en)
TW (2) TW201703796A (en)
WO (1) WO2010075238A1 (en)
ZA (1) ZA201105418B (en)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2664854T3 (en) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh antagonist antibodies directed against a calcitonin gene-related peptide to treat cluster headache
EP2220118A2 (en) * 2007-11-21 2010-08-25 Amgen Inc. Wise binding antibodies and epitopes
BRPI0907135A2 (en) 2008-03-04 2015-07-14 Pfizer Ltd chronic pain treatment processes
CN103748111B (en) 2011-05-20 2018-04-27 奥尔德生物控股有限责任公司 Compositions and the use of anti-cgrp
AU2012258980B8 (en) 2011-05-20 2017-06-15 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
TW201808332A (en) 2011-05-20 2018-03-16 Alderbio Holdings Llc Use of ANTI-CGRP or ANTI-CGRP-R antibodies or antibody fragments to treat or prevent chronic and acute forms of diarrhea
AU2014236867A1 (en) * 2013-03-15 2015-09-24 Amgen Inc. Methods and compositions relating to anti-CCR7 antigen binding proteins
PE19232015A1 (en) * 2013-03-15 2016-01-14 Amgen Inc PAC1 human antibodies
SG11201602876WA (en) 2013-10-24 2016-05-30 Amgen Inc Injector and method of assembly
MX2016005315A (en) 2013-10-24 2016-08-11 Amgen Inc Drug delivery system with temperature-sensitive control.
US20180193623A1 (en) 2014-02-05 2018-07-12 Amgen Inc. Drug delivery system with electromagnetic field generator
WO2015143409A1 (en) * 2014-03-21 2015-09-24 Labrys Biologics, Inc. Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP2017518791A (en) 2014-05-07 2017-07-13 アムジエン・インコーポレーテツド Injector having a shock absorbing element
WO2015187805A2 (en) 2014-06-03 2015-12-10 Amgen Inc. Systems and methods for supporting patient use of a drug delivery device
JP2017533694A (en) 2014-09-15 2017-11-16 アムジェン インコーポレイテッド Bispecific anti cgrp receptor / PAC1 receptor antigen binding proteins and uses thereof
AU2015332557A1 (en) 2014-10-14 2017-03-02 Amgen Inc. Drug injection device with visual and audio indicators
JP2017538511A (en) 2014-12-19 2017-12-28 アムジエン・インコーポレーテツド Proximity sensor with a drug delivery device
WO2016100055A1 (en) 2014-12-19 2016-06-23 Amgen Inc. Drug delivery device with live button or user interface field
US20180036476A1 (en) 2015-02-17 2018-02-08 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
US20180193562A1 (en) 2015-02-27 2018-07-12 Amgen Inc. Drug delivery device having a needle guard mechanism with a turnable threshold of resistance to needle guard movement
TW201637667A (en) 2015-04-24 2016-11-01 Amgen Inc Methods for treating or preventing migraine headache
US20180141989A1 (en) * 2015-05-13 2018-05-24 The Board Of Regents Of The University Of Oklahoma Variants of Adrenomedullin and Calcitonin Gene-Related Peptide and Methods of Use
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
WO2017120178A1 (en) 2016-01-06 2017-07-13 Amgen Inc. Auto-injector with signaling electronics
US20190050375A1 (en) 2016-03-15 2019-02-14 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
WO2017192287A1 (en) 2016-05-02 2017-11-09 Amgen Inc. Syringe adapter and guide for filling an on-body injector
WO2017197222A1 (en) 2016-05-13 2017-11-16 Amgen Inc. Vial sleeve assembly
EP3458988A1 (en) 2016-05-16 2019-03-27 Amgen Inc. Data encryption in medical devices with limited computational capability
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1 (en) 2016-08-17 2018-02-22 Amgen Inc. Drug delivery device with placement detection
CA3036632A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
WO2018055573A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating cluster headache
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
WO2018132572A1 (en) * 2017-01-11 2018-07-19 The Board Of Trustees Of The Leland Stanford Junior University R-spondin (rspo) surrogate molecules
WO2018152073A1 (en) 2017-02-17 2018-08-23 Amgen Inc. Insertion mechanism for drug delivery device
US20190085061A1 (en) 2017-03-02 2019-03-21 Beth Israel Deaconess Medical Center, Inc. Selecting headache patients responsive to antibodies directed against calcitonin gene related peptide
WO2018164829A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
WO2018165499A1 (en) 2017-03-09 2018-09-13 Amgen Inc. Insertion mechanism for drug delivery device
WO2019014014A1 (en) 2017-07-14 2019-01-17 Amgen Inc. Needle insertion-retraction system having dual torsion spring system

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
AU597574B2 (en) 1986-03-07 1990-06-07 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (en) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele with einzelpolypeptidkette.
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JPH02229119A (en) 1989-02-28 1990-09-11 Toyo Jozo Co Ltd Preventive and remedy for arteriosclerosis
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
DE69133566D1 (en) 1990-01-12 2007-04-26 Amgen Fremont Inc Formation of xenogenic antibodies
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DK0546073T3 (en) 1990-08-29 1998-02-02 Genpharm Int Making and using transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0575319T3 (en) 1991-03-11 2000-07-10 Univ Georgia Res Found Cloning and expression of the Renilla luciferase
EP0590076A4 (en) 1991-06-14 1997-02-12 Dnx Corp Production of human hemoglobin in transgenic pigs
DE69224906D1 (en) 1991-07-08 1998-04-30 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
DE69324579T2 (en) * 1992-03-17 1999-09-23 Novartis Ag Genetically engineered antibodies
JP3589665B2 (en) 1992-10-23 2004-11-17 イミュネックス・コーポレーションImmunex Corporation Preparation of soluble oligomeric proteins
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
EP0759170B1 (en) 1993-09-10 2008-07-09 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
WO1996003993A2 (en) 1994-08-05 1996-02-15 The Rockefeller University Modulation of thymocyte and t cell functional activity
DE69433747D1 (en) 1994-08-16 2004-06-03 Human Genome Sciences Inc Calcitoninrezeptor
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
DE69637481D1 (en) 1995-04-27 2008-05-15 Amgen Fremont Inc Dating from immunized Xenomäusen human antibodies to IL-8
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6255455B1 (en) * 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
CA2273194C (en) 1996-12-03 2011-02-01 Abgenix, Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
DE19732944A1 (en) 1997-07-31 1999-02-04 Thomae Gmbh Dr K Derivatives of calcitonin-gene-related peptide fragment
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
WO1999049019A2 (en) 1998-03-27 1999-09-30 Prolume, Ltd. Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics
US6268474B1 (en) 1998-04-30 2001-07-31 Creighton University Peptide antagonists of CGRP-receptor superfamily and methods of use
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
US20020090646A1 (en) 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
FR2821080B1 (en) 2001-02-20 2003-12-19 Sanofi Synthelabo specific antibodies of human adrenomedullin pharmaceutical composition thereof, its therapeutic applications
EP1438325B1 (en) 2001-09-27 2009-12-30 Merck & Co., Inc. Isolated dna molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
AR039067A1 (en) * 2001-11-09 2005-02-09 Pfizer Prod Inc CD40 antibodies
US20040110170A1 (en) 2002-05-18 2004-06-10 The Regents Of The University Of California Cloning and characterization of calcitonin gene related peptide receptors
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
WO2004097421A2 (en) 2003-04-29 2004-11-11 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
EP2417980A1 (en) 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Hybrid polypeptides with selectable properties
US7423128B2 (en) * 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
US20080267971A1 (en) 2004-12-21 2008-10-30 Green Larry L Antibodies Directed to Angiopoietin-2 and Uses Thereof
JP4993606B2 (en) 2005-06-16 2012-08-08 隆行 新藤 Stabilizers vasculature targeting Ramp2 and angiogenesis agents
GB0521139D0 (en) 2005-10-18 2005-11-23 Univ Sheffield Therapeutic agent
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
ES2664854T3 (en) 2005-11-14 2018-04-23 Teva Pharmaceuticals International Gmbh antagonist antibodies directed against a calcitonin gene-related peptide to treat cluster headache
WO2007076336A1 (en) * 2005-12-22 2007-07-05 Eli Lilly And Company Treatment of migraine with anti-cgrp antibodies
EP2064244A2 (en) * 2006-08-03 2009-06-03 AstraZeneca AB ANTIBODIES DIRECTED TO alphaVß6 AND USES THEREOF
GB0708002D0 (en) * 2007-04-25 2007-06-06 Univ Sheffield Antibodies
CA2716799C (en) 2008-03-04 2018-05-22 Pfizer Limited Methods of treating inflammatory pain
FR2934597B1 (en) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Antibody binding to receptors adrenomedullin and their use as a medicine.
RU2535074C2 (en) 2009-08-28 2014-12-10 Лэйбрис Байолоджикс, Инк. Method of treating visceral pain by administering antagonist antibodies against calcitonin gene-related peptide
US9401875B2 (en) 2012-06-01 2016-07-26 Nippon Telegraph And Telephone Corporation Packet transfer processing method and packet transfer processing device
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof

Also Published As

Publication number Publication date
AU2009330175B2 (en) 2014-01-16
TWI574697B (en) 2017-03-21
TN2011000283A1 (en) 2012-12-17
SG172307A1 (en) 2011-07-28
HUS1800047I1 (en) 2018-12-28
LT2379594T (en) 2017-11-27
DK2379594T3 (en) 2017-10-30
US20130071410A1 (en) 2013-03-21
SI2379594T1 (en) 2017-12-29
JP6261132B2 (en) 2018-01-17
JP2014210815A (en) 2014-11-13
ZA201105418B (en) 2012-02-29
US20150376286A1 (en) 2015-12-31
US9862771B2 (en) 2018-01-09
CN102348722B (en) 2016-06-08
NZ623541A (en) 2015-12-24
CA2746858C (en) 2017-10-03
EA031320B1 (en) 2018-12-28
WO2010075238A1 (en) 2010-07-01
PE04272012A1 (en) 2012-05-13
NL300961I2 (en) 2019-01-15
EP3184546A1 (en) 2017-06-28
AU2009330175A1 (en) 2011-06-23
CR20110400A (en) 2011-10-12
IL243784A (en) 2016-11-30
HUE034506T2 (en) 2018-02-28
IL213429A (en) 2016-02-29
JP2012513214A (en) 2012-06-14
US20180142029A1 (en) 2018-05-24
TW201032823A (en) 2010-09-16
JP2016026224A (en) 2016-02-12
LTPA2018017I1 (en) 2019-01-10
CY1119465T1 (en) 2018-03-07
HRP20171690T1 (en) 2017-12-15
RS56567B1 (en) 2018-02-28
IL243784D0 (en) 2016-04-21
CN102348722A (en) 2012-02-08
AR074857A1 (en) 2011-02-16
IL213429D0 (en) 2011-07-31
EP2379594A1 (en) 2011-10-26
NO2018042I1 (en) 2018-12-17
ES2643835T3 (en) 2017-11-24
EA201100892A1 (en) 2012-01-30
US9102731B2 (en) 2015-08-11
JP5761805B2 (en) 2015-08-12
EP2379594B1 (en) 2017-08-09
KR20180043850A (en) 2018-04-30
EA201891500A2 (en) 2018-11-30
MX2011006804A (en) 2011-09-27
BRPI0922505A2 (en) 2016-07-05
KR101740615B1 (en) 2017-05-26
KR20110106409A (en) 2011-09-28
AU2009330175C1 (en) 2018-10-04
PT2379594T (en) 2017-11-16
CO6400232A2 (en) 2012-03-15
KR20170061182A (en) 2017-06-02
TW201703796A (en) 2017-02-01
MA32982B1 (en) 2012-01-02
CA2746858A1 (en) 2010-07-01
US20100172895A1 (en) 2010-07-08
KR101853393B1 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
TWI578998B (en) Anti-il-6 receptor antibody
TWI461211B (en) Anti-her antibodies
TWI541021B (en) Il-17 binding proteins
TWI396549B (en) Antibodies against human angiopoietin 2
EP2370466B8 (en) Human anti-alpha-synuclein autoantibodies
IL216620D0 (en) Bispecific, tetravalent antigen binding proteins
TWI595005B (en) Human c-fms antigen binding proteins
EP2114273A4 (en) Taper-locking fixation system
IL206297A (en) Binding molecules to the human ox40 receptor
EP2077859A4 (en) Antibody formulation
ZA201100058B (en) Prostaglandin e2 binding proteins and uses thereof
EP2069401A4 (en) Multispecific epitope binding proteins and uses thereof
TWI486166B (en) Stabilized receptor polypeptides and uses thereof
HK1138790A1 (en) Anti-sclerostin antibodies
IL201227A (en) Stitched polypeptides
IL211763D0 (en) Folate receptor binding conjugates of antifolates
IL197479A (en) Antibody which specifically binds human interleukin-4 receptor
HK1217511A1 (en) Binding proteins comprising vl domains vl
EP2262837A4 (en) Pd-1 binding proteins
ZA201108536B (en) Bispecific antigen binding proteins
IL210268D0 (en) Tgf - ?? antagonist multi - target binding proteins
EP2215246A4 (en) Protein scaffolds
TWI508745B (en) Tnf-α binding proteins
HRP20141249T1 (en) Antibody formulation
ZA201002422B (en) Modified antibody constant region